RxDoctor Payments DataLook up a doctor →

Seth Kareus, MD

Neurology · Grand Junction, CONPI 1639354376

Payments from drug & device makers

$193,263in general payments, 2019–2025

Across 388 payments — averaging $498.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$165K
  • Livanova USA, Inc.$10K
  • Teva Pharmaceuticals USA, Inc.$10K
  • AbbVie$4K
  • Novartis$484
  • Biogen$472
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$4,2255%
  • Speaking & faculty fees$67,79974%
  • Travel & lodging$10,86112%
  • Food & beverage$8,2879%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$193,263 in reported general payments places this provider in the 85th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$321,813
Medicare patients
507
Services billed
30,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine28$296,999
IngrezzaValbenazine Tosylate27$208,891
Kesimpta PenOfatumumab23$192,875
BetaseronInterferon Beta-1b14$137,653
NeuproRotigotine45$52,115
LinzessLinaclotide47$41,704
QuliptaAtogepant33$40,992
RytaryCarbidopa/Levodopa30$38,046
Nurtec OdtRimegepant Sulfate18$36,862
UbrelvyUbrogepant26$27,380
Carbidopa-LevodopaCarbidopa/Levodopa687$24,588
NuedextaDextromethorphan Hbr/Quinidine12$21,866
Emgality PenGalcanezumab-Gnlm26$20,728
Dalfampridine ErDalfampridine33$18,529
OngentysOpicapone15$16,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$9,974$296,99928 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$104$225,72842 claims
AbbVieLinzess, Qulipta, Ubrelvy$4,174$110,077106 claims
UCB, Inc.Neupro$142$52,11545 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$68$40,45349 claims
PfizerNurtec Odt$21$36,86218 claims
Avanir Pharmaceuticals, Inc.Nuedexta$58$21,86612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 334 neurology providers in Colorado.

Other neurology in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →